Document Detail


A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
MedLine Citation:
PMID:  1576071     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The side effect profiles and lipid lowering efficacy of nicotinic acid (1 g three times daily) and its analogue acipimox (250 mg three times daily) in type 2b hyperlipidaemia were compared in a double-blind placebo controlled study. In the nicotinic acid group (n = 7) at 12 weeks there were significant reductions (P less than 0.05) with respect to placebo (n = 9) in total cholesterol (median and range) 6.6 mmol l-1 (4.8-8.4) vs 8.8 mmol l-1 (7.5-9.5), triglyceride 1.4 mmol l-1 (0.5-4.6) vs 2.8 mmol l-1 (1.5-9.5) and apoprotein B 88.6 mg dl-1 (62.1-114) vs 121.9 mg dl-1 (88.0-170.7). In contrast there was no significant alteration in lipids in the acipimox group (n = 12). Nicotinic acid was associated with a high incidence of side effects, principally cutaneous flushing, while acipimox was well tolerated by all patients.
Authors:
M J O'Kane; T R Trinick; M B Tynan; E R Trimble; D P Nicholls
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  33     ISSN:  0306-5251     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  1992 Apr 
Date Detail:
Created Date:  1992-06-11     Completed Date:  1992-06-11     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  451-3     Citation Subset:  IM    
Affiliation:
Royal Victoria Hospital, Belfast, Northern Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antilipemic Agents / therapeutic use*
Female
Humans
Hyperlipidemias / drug therapy*
Lipids / blood
Male
Middle Aged
Niacin / adverse effects,  therapeutic use*
Pyrazines / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Lipids; 0/Pyrazines; 51037-30-0/acipimox; 59-67-6/Niacin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling fr...
Next Document:  Effect of high ambient temperature on the kinetics of the pupillary light reflex in healthy voluntee...